IP Library Granted Patent US 9,974,840
Granted Patent B2
US 9,974,840 · App. 14/024,081 · Granted May 22, 2018

Human placental collagen compositions, and methods of making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,974,840
App. No.
14/024,081
Granted
May 22, 2018
Kind
B2
Abstract

The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.

Claims (20)

1. A method of augmenting tissue repair in a subject comprising contacting said tissue with a composition comprising human placental extracellular matrix, wherein said human placental extracellular matrix comprises (i) placental collagen that comprises between 74% and 90% Type I collagen, between 4% to 6% Type III collagen, and between 2% to 15% type IV collagen (ii) no detectable amounts of fibronectin or laminin, and (iii) additional extracellular matrix components selected from the following groups:

(a) 4.7% elastin by dry weight and 0.28% glycosaminoglycans by dry weight;

(b) 3.2% elastin by dry weight and 0.34% glycosaminoglycans by dry weight;

(c) 4.4% elastin by dry weight and 0.38% glycosaminoglycans by dry weight; and

(d) 3.5% elastin by dry weight and 0.59% glycosaminoglycans by dry weight.

2. The method of claim 1 , wherein said tissue is internal to the subject.

3. The method of claim 1 , wherein said tissue is wrapped with the composition.

4. A method of replacing tissue of a subject, comprising administering to the subject a composition comprising human placental extracellular matrix, wherein said human placental extracellular matrix comprises (i) placental collagen that comprises between 74% and 92% Type I collagen, 4% to 6% Type III collagen, and between 2% to 15% type IV collagen (ii) no detectable amounts of fibronectin or laminin, and (iii) additional extracellular matrix components selected from the following groups:

(a) 4.7% elastin by dry weight and 0.28% glycosaminoglycans by dry weight;

(b) 3.2% elastin by dry weight and 0.34% glycosaminoglycans by dry weight;

(c) 4.4% elastin by dry weight and 0.38% glycosaminoglycans by dry weight; and

(d) 3.5% elastin by dry weight and 0.59% glycosaminoglycans by dry weight.

5. The method of claim 4 , wherein said tissue comprises a barrier in the brain.

6. The method of claim 4 , wherein said composition is shaped as a nerve guide.

7. The method of claim 6 , wherein said composition is shaped as a tube.

8. The method of claim 4 , wherein said tissue is a tendon.

9. The method of claim 1 , wherein the composition further comprises placental stem cells that are allogeneic to the subject.

10. The method of claim 1 , wherein the composition further comprises placental stem cells that are autologous to the subject.

11. The method of claim 4 , wherein the composition further comprises placental stem cells that are allogeneic to the subject.

12. The method of claim 4 , wherein the composition further comprises placental stem cells that are autologous to the subject.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2025
From: CELULARITY INC.
To: CELENIV PTE. LTD.
Reel/Frame 073705/0109 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2018
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 045209/0509 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2017
From: CLARITY ACQUISITION II LLC
To: CELULARITY, INC.
Reel/Frame 044780/0261 →
MERGER Recorded Nov 8, 2017
From: ANTHROGENESIS CORPORATION
To: CLARITY ACQUISITION II LLC
Reel/Frame 044413/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2013
From: BHATIA, MOHIT; LUGO, CHRIS; YE, QIAN; EDINGER, JAMES W.
To: ANTHROGENESIS CORPORATION
Reel/Frame 031185/0428 →